Strs Ohio Purchases Shares of 29,300 Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Strs Ohio purchased a new stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 29,300 shares of the company’s stock, valued at approximately $335,000. Strs Ohio owned about 0.07% of Voyager Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its position in shares of Voyager Therapeutics by 76.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 199,492 shares of the company’s stock valued at $2,284,000 after purchasing an additional 86,327 shares in the last quarter. Armistice Capital LLC boosted its position in shares of Voyager Therapeutics by 3.8% during the 1st quarter. Armistice Capital LLC now owns 3,524,000 shares of the company’s stock valued at $27,170,000 after purchasing an additional 128,000 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at about $319,000. Denali Advisors LLC bought a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at about $175,000. Finally, HarbourVest Partners LLC bought a new stake in shares of Voyager Therapeutics during the 1st quarter valued at about $476,000. Institutional investors own 58.81% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, insider Todd Alfred Carter sold 10,500 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $8.16, for a total value of $85,680.00. Following the completion of the sale, the insider now directly owns 54,360 shares of the company’s stock, valued at $443,577.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Peter P. Pfreundschuh sold 13,567 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $6.99, for a total value of $94,833.33. Following the completion of the transaction, the chief financial officer now directly owns 149,433 shares of the company’s stock, valued at $1,044,536.67. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Todd Alfred Carter sold 10,500 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $8.16, for a total value of $85,680.00. Following the transaction, the insider now directly owns 54,360 shares of the company’s stock, valued at $443,577.60. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Oppenheimer restated an “outperform” rating and set a $16.00 target price on shares of Voyager Therapeutics in a research report on Monday, August 7th. StockNews.com assumed coverage on Voyager Therapeutics in a research note on Thursday, October 5th. They set a “hold” rating on the stock. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of Voyager Therapeutics in a research note on Monday, September 18th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Voyager Therapeutics Stock Performance

VYGR stock opened at $6.57 on Wednesday. The stock’s 50 day simple moving average is $8.04 and its 200 day simple moving average is $9.49. Voyager Therapeutics, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $14.34. The company has a market cap of $288.42 million, a P/E ratio of 2.89 and a beta of 1.09.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.08. The company had revenue of $4.85 million during the quarter, compared to analysts’ expectations of $2.00 million. Equities analysts predict that Voyager Therapeutics, Inc. will post 1.11 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.